- Home
- QMCO vs CNTB Comparison
QMCO vs CNTB Comparison
Compare QMCO & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QMCO | CNTB |
|---|---|---|
| Founded | 1980 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.1M | 140.4M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | QMCO | CNTB |
|---|---|---|
| Price | $30.34 | $0.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $26.50 | $5.88 |
| AVG Volume (30 Days) | 1.6M | ★ 2.0M |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $372,827,000.00 | $64,000.00 |
| Revenue This Year | $18.93 | $11,292.89 |
| Revenue Next Year | $13.67 | $114.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.65 | N/A |
| 52 Week Low | $4.19 | $0.85 |
| 52 Week High | $35.65 | $3.82 |
Technical Indicators
Market Signals| Indicator | QMCO | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | 38.92 |
| Support Level | $5.54 | N/A |
| Resistance Level | N/A | $2.76 |
| Average True Range (ATR) | 3.07 | 0.09 |
| MACD | -0.34 | 0.00 |
| Stochastic Oscillator | 51.03 | 5.86 |
Price Performance
Historical ComparisonAbout QMCO Quantum Corporation
Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data in the era of artificial intelligence (AI). It provides one of the comprehensive and cost-efficient solutions for the entire data lifecycle. The group provides solutions for video, images, audio, and other large files because this unstructured data represents. Its portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The group operates in three geographic regions: Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC).
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.